<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38718">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602366</url>
  </required_header>
  <id_info>
    <org_study_id>Quatro</org_study_id>
    <nct_id>NCT02602366</nct_id>
  </id_info>
  <brief_title>The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy</brief_title>
  <official_title>The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy Among Young Women in Zimbabwe and South Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CONRAD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UZ-UCSF Collaborative Research Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Match Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CONRAD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of The Quatro Study is to assess the acceptability, preferences, user experience
      and effect on sexual behavior of four different vaginal microbicide or multi-purpose
      technology (MPT) delivery forms, using placebo products in 18-30 year old African women:
      rapidly disintegrating vaginal insert, intravaginal ring (IVR), film and gel. The study also
      examines adherence to the dosage forms through objective markers, developed for each dosage
      form prior to the commencement of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ratings and relative preference rankings of four vaginal delivery forms</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3, Month 4, Month 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attributes least and most favored for the vaginal delivery forms as measured by discreet choice experiment</measure>
    <time_frame>Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence assessed by self report via questionnaire</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3, Month 4, Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence assessed by objective biomarkers, utilizing antibodies, tagged recombinant proteins, biochemical assays and/or spectroscopy</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3, Month 4, Month 5</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>HIV</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Month 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Month 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Month 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Month 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HEC Placebo Gel</intervention_name>
    <arm_group_label>Month 1</arm_group_label>
    <arm_group_label>Month 2</arm_group_label>
    <arm_group_label>Month 3</arm_group_label>
    <arm_group_label>Month 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Vaginal Insert</intervention_name>
    <arm_group_label>Month 1</arm_group_label>
    <arm_group_label>Month 2</arm_group_label>
    <arm_group_label>Month 3</arm_group_label>
    <arm_group_label>Month 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Vaginal Film</intervention_name>
    <arm_group_label>Month 1</arm_group_label>
    <arm_group_label>Month 2</arm_group_label>
    <arm_group_label>Month 3</arm_group_label>
    <arm_group_label>Month 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Intravaginal ring (IVR)</intervention_name>
    <arm_group_label>Month 1</arm_group_label>
    <arm_group_label>Month 2</arm_group_label>
    <arm_group_label>Month 3</arm_group_label>
    <arm_group_label>Month 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-30

          -  In good health, as determined by the site Investigator or designee based on clinical
             history

          -  Willing and able to comply with study procedures and attend monthly follow-up visits

          -  Willing and able to provide informed consent

          -  Fluent in one of the languages being used in the study (English, Shona or Zulu)

          -  Not intending to travel or move out of the research catchment area for the next 6
             months

          -  Sexually active defined by vaginal intercourse with a male at least 4 times per month
             in the past 3 months and plan to be sexually active during the study duration

        Exclusion Criteria:

          -  HIV positive

          -  Pregnant, or intention to become pregnant during the clinical study

          -  Prior participation in any HIV-prevention or MPT product demonstration study or
             clinical trial

          -  Any current or historical health (including vaginal or genitourinary conditions) or
             psychological issues that the site Investigator or his/her designee determines should
             exclude the potential participant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Schwartz, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CONRAD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah A Littlefield, MPH</last_name>
    <phone>(703) 276-4033</phone>
    <email>slittlefield@conrad.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Linton, MHS</last_name>
    <phone>(703) 276 4021</phone>
    <email>klinton@conrad.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MatCH Research</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenni Smit</last_name>
    </contact>
    <contact_backup>
      <last_name>Mags Beksinska</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Zimbabwe-University of California San Francisco Collaborative Research Program (UZ-UCSF)</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Z. M. Chirenje, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Nyaradzo Mgodi</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 29, 2016</lastchanged_date>
  <firstreceived_date>November 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>DCE</keyword>
  <keyword>MPT</keyword>
  <keyword>Microbicide</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
